Dr. Mullally is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
77 Avenue Louis Pasteur
Harvard Institutes of Medicine Building, Room 738
Boston, MA 02115Phone+1 617-525-4980
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2010
- Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
- University College of Dublin National Univ SOMClass of 1999
Certifications & Licensure
- MA State Medical License 2005 - 2026
- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 126 citationsDepletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.Ann Mullally, Claudia Bruedigam, Luke Poveromo, Florian H. Heidel, Amy Purdon
Blood. 2013-05-02 - 34 citationsJAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint responseEdwin Chen, Jong Sook Ahn, Charles E. Massie, David Clynes, Anna L. Godfrey
Proceedings of the National Academy of Sciences of the United States of America. 2014-10-21 - 292 citationsPhysiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsAnn Mullally, Steven W. Lane, Brian Ball, Christine Megerdichian, Rachel Okabe
Cancer Cell. 2010-06-15
Abstracts/Posters
- Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of ResponseAnn Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Zinc-Dependent Homomultimerization of Mutant Calreticulin Is Required for MPN PathogenesisAnn Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy of the Pan-Bcl-2 Inhibitor (Obatoclax) As a Single Agent to Treat Myeloproliferative Neoplasm in JAK2V617F Murine Transplantation ModelAnn Mullally, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Friday Scientific Workshop on the Interplay Between Coagulation and Malignancy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- As If Myeloproliferative Neoplasms Weren't Already Challenging Enough60th American Society of Hematology Annual Meeting - 12/2/2018
- Join now to see all
Press Mentions
- Harvard Researchers Discover Some Cancers May Originate Decades Earlier Than Previously BelievedMarch 12th, 2021
- Original Error: Retracing the History of the Mutation That Gave Rise to Cancer Decades LaterMarch 10th, 2021
- Splicing Factor YBX1 Mediates Persistence of JAK2-Mutated NeoplasmsNovember 25th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: